CO1 Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis
To update the published network meta-analysis (NMA) from Burnett et al. 2022 comparing the efficacy of non-statin lipid-lowering therapies inclisiran, evolocumab, alirocumab, bempedoic acid, and ezetimibe in patients with hypercholesterolemia and/or increased cardiovascular risk having elevated low-density lipoprotein cholesterol (LDL-C) despite taking maximally-tolerated dose statins. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: H. Burnett, B. Neupane, V. Pierre, K. Fahrbach, A. Cichewicz, H. Natani, D. Bhowmik, A. Reichelt, K. Buesch, R. Jindal Tags: Clinical Outcomes Source Type: research
EE461 An Italian Real-World Analysis of Economic Impact in Patients with Hypercholesterolemia Treated with Rosuvastatin/Ezetimibe as Free Vs Single-Pill Combination
This real-world analysis evaluated clinical characteristics and economic impact for the Italian National Health System in patients receiving rosuvastatin/ezetimibe (ROS/EZE) as free (FC) vs single-pill combination (SPC). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Degli Esposti, L. Perez, M. Dovizio, C. Veronesi, A. Zambon, E. Liberopoulos Source Type: research
Comparative treatment of Sulfasalazine+Ezetimibe combination and Sulfasalazine in a rat model with induced colitis
J Med Life. 2023 Aug;16(8):1165-1169. doi: 10.25122/jml-2023-0194.ABSTRACTUlcerative colitis is a chronic inflammatory disease with high mortality and morbidity worldwide. It causes inflammation in the lining of the colon, resulting in several symptoms that negatively impact the quality of life. Unfortunately, there is currently no known cure for this condition. Therefore, it is crucial to explore alternative treatment approaches. This research aimed to investigate the anti-inflammatory and antioxidative effects of a combination therapy involving Sulfasalazine+Ezetimibe compared to Sulfasalazine alone in a rat model of ulc...
Source: Journal of Medicine and Life - November 29, 2023 Category: General Medicine Authors: Farrah Rasool Jaafar Ahmed Abu-Raghif Source Type: research
